Novartis’ Multiple Sclerosis Pill Faces FDA Review (Update1)

[guest]

Novartis AG's drug Gilenia has risks that may outweigh its benefit in treating multiple sclerosis, according to U.S. regulators reviewing whether to approve the first pill to slow progression of the disease.


More...

Toggle signature
||||| Mentor Group Access Now! |||||